DIAGNOS Announces that its Client in California, the Chaparral Medical Group of Clinics, is Reopening the Screening Services ...
July 07 2020 - 10:41AM
Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK)
(OTCQB: DGNOF), a leader in early detection of critical health
issues using advanced Artificial Intelligence (AI), is pleased to
announce that its client, Chaparral Medical Group (“Chaparral”), is
reopening amid additional safety extra measures being implemented
to address the COVID-19 situation.
Dr. Prasad Jeereddi, MD,
Diabetes Specialist, President, and Medical Director of
Chaparral stated: “The remote screenings are
conducted using a telemedicine application which temporarily
replaces the requirement for patients to be seen in person by a
specialist. It only takes 5 minutes to perform the screening test.
It prevents the need for the diabetic patient to get their eyes
tested in a different location. Chaparral operates 33 clinics
across the state of California. Diabetic patients are vulnerable to
COVID-19 and the convenience of the test in our clinic reduces the
risk for COVID-19 exposure.”
Telemedicine refers to the practice of
caring for patients remotely when the provider and patient are not
physically present with each other.
Mr. Yves-Stephane Couture,
vice-president of sales at DIAGNOS added: “We are
pleased to provide extra service at the point of care (POC) for
Chaparral’s patients. While the patient is in the clinic, it’s an
excellent opportunity to check their eyes for diabetic retinopathy.
Diabetes is the most common cause of vision impairment and
blindness among working-age adults in the United States as per the
US Centers for Disease Control and Prevention.”
About Chaparral Medical GroupChaparral Medical
Group is a multi-specialty healthcare group serving the communities
of Claremont, La Verne, San Dimas, Fontana, Pomona, Rancho
Cucamonga, Upland, Chino Hills and Diamond Bar in Southern
California. Over 20 primary care physicians serve as the group’s
clinical core, and work together with their medical and surgical
specialists to provide outstanding care to the patient population
of Southern California. They have been serving the community since
1978 and their unwavering commitment to patient care and physician
work satisfaction are what have driven them to become the most
trusted and relied-upon group of physicians in their area. About
DIAGNOSDIAGNOS is a publicly-traded Canadian corporation with a
mission of early detection of critical health issues through the
use of its Artificial Intelligence (“AI”) tool CARA (Computer
Assisted Retina Analysis). CARA is a tele-ophthalmology platform
that integrates with existing equipment (hardware and software) and
processes at the point of care. CARA’s Artificial Intelligence
image enhancement algorithms make standard retinal images sharper,
clearer and easier to read. CARA is accessible securely over the
internet and is compatible with all recognized image formats and
brands of fundus cameras and is EMR compatible. CARA is a
cost-effective tool for screening large numbers of patients in
real-time. CARA complies with local regulations, is FDA cleared for
commercialization in the United States of America is Health Canada
licensed for commercialization in Canada and is CE marking
compliant in Europe.
Additional information is available at
www.diagnos.com and www.sedar.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Apr 2023 to Apr 2024